Steven K. Burke - 02 Feb 2026 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role
SVP, Chief Medical Officer
Signature
/s/ Carolyn M. Rucci, attorney-in-fact for Steven K. Burke
Issuer symbol
AKBA
Transactions as of
02 Feb 2026
Net transactions value
-$94,045
Form type
4
Filing time
04 Feb 2026, 16:13:17 UTC
Previous filing
03 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Burke Steven Keith SVP, Chief Medical Officer C/O AKEBIA THERAPEUTICS, INC, 245 FIRST STREET, CAMBRIDGE /s/ Carolyn M. Rucci, attorney-in-fact for Steven K. Burke 04 Feb 2026 0001619834

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKBA Common Stock Sale $29,999 -21,582 -2.1% $1.39 994,508 02 Feb 2026 Direct F1, F2
transaction AKBA Common Stock Sale $35,271 -25,375 -2.6% $1.39 969,133 02 Feb 2026 Direct F1, F3
transaction AKBA Common Stock Sale $28,774 -20,701 -2.1% $1.39 948,432 02 Feb 2026 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2023.
F2 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2023.
F3 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024.
F4 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025.